Curis
ProfileJobs (3)

Curis

Suggest Edit
    • Healthcarebiotechdrug developmenthealthtechoncology

    Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907 which is being investigated in clinical studies in patients with lymphomas and solid tumors. It is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, the Company has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas. 

    Revenue(FY, 2017)
    $9.9 M
    Market capitalization(2018-12-14)
    $27.8 M

    Employee Rating

    3.6More
    TypePublic
    HQLexington, US
    Founded2000
    Size (employees)55 (est)-5%
    Websitecuris.com
    Curis was founded in 2000 and is headquartered in Lexington, US
    Report incorrect company information

    Viewing summary data as a guest

    Sign up for free to see all data

    Curis Office Locations

    Curis has an office in Lexington
    Lexington, US (HQ)
    4 Maguire Rd
    Show all (1)
    Report incorrect company information

    Curis Financials and Metrics

    Curis Revenue

    Curis's revenue was reported to be $9.90 m in FY, 2017
    USD

    Revenue (Q3, 2018)

    		2.8m

    Net income (Q3, 2018)

    		(7.2m)

    EBIT (Q3, 2018)

    		(6.4m)

    Market capitalization (14-Dec-2018)

    		27.8m

    Closing stock price (14-Dec-2018)

    		0.8

    Cash (30-Sep-2018)

    		25.6m

    EV

    		39.4m
    Curis's current market capitalization is $27.8 m.
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Revenue

    		15.0m9.8m7.9m7.5m9.9m

    Revenue growth, %

    		(34%)(20%)(4%)

    General and administrative expense

    		11.3m12.9m15.6m14.1m

    R&D expense

    		1.1m26.7m31.6m45.1m
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

    Revenue

    		7.2m1.3m4.8m1.8m1.7m2.1m2.0m1.7m1.7m1.8m2.1m2.1m2.4m2.5m2.4m2.8m

    General and administrative expense

    		2.8m2.8m2.9m2.7m3.5m3.4m2.8m3.6m3.4m4.7m3.5m3.8m3.4m4.0m3.6m4.1m

    R&D expense

    		121.9k3.1m3.3m3.7m4.7m5.9m4.0m6.8m8.8m6.8m13.5m11.3m13.4m8.3m6.5m5.0m

    Operating expense total

    		7.1m6.0m6.3m6.5m32.7m9.5m6.9m10.5m12.4m29.5m17.2m15.2m16.9m12.4m10.2m9.3m
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Cash

    		9.6m7.7m33.1m26.0m38.3m

    Accounts Receivable

    		1.5m2.0m2.1m2.5m3.1m

    Inventories

    		495.3k489.8k1.2m1.3m

    Current Assets

    		60.2m52.2m85.5m48.2m64.3m
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

    Cash

    		13.8m7.9m10.2m7.9m23.5m31.5m28.7m14.7m8.6m20.7m42.4m26.7m49.8m24.7m30.5m25.6m

    Accounts Receivable

    		1.2m1.4m4.8m1.8m1.8m2.1m2.3m1.7m1.9m1.9m2.2m2.2m2.5m2.5m2.5m2.9m

    Current Assets

    		64.9m59.6m61.0m57.1m102.6m102.1m96.6m75.8m64.5m56.6m64.4m54.4m73.0m51.9m43.7m34.8m

    PP&E

    		467.5k408.6k439.4k407.4k364.0k323.1k315.5k383.6k451.0k406.0k410.0k426.0k384.0k390.0k352.0k312.0k
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Net Income

    		(12.3m)(18.7m)(59.0m)(60.4m)(53.3m)

    Depreciation and Amortization

    		141.5k155.1k160.8k193.0k235.0k

    Inventories

    Accounts Payable

    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

    Net Income

    		(8.1m)(5.6m)(7.5m)(13.0m)(31.8m)(40.0m)(45.5m)(9.4m)(20.7m)(49.1m)(15.7m)(29.8m)(45.3m)(10.7m)(19.4m)(26.6m)

    Depreciation and Amortization

    		104.4k37.0k74.8k114.1k82.4k123.1k34.3k90.0k141.0k55.0k113.0k176.0k53.0k99.0k139.0k

    Accounts Payable

    		436.4k395.2k345.5k2.8m(154.0k)75.6k4.9m3.9m5.1m5.9m

    Cash From Operating Activities

    		(4.0m)(10.0m)(12.1m)(14.5m)(19.0m)(8.0m)(18.8m)(26.4m)(15.1m)(24.4m)(40.8m)(10.0m)(16.9m)(25.1m)
    show all
    USDY, 2018

    EV/EBIT

    		-6.1 x

    EV/CFO

    		-1.6 x

    Financial Leverage

    		56.6 x
    Show all financial metrics
    Report incorrect company information

    Competitors

    Ourotech
    Healthcare - Private
    Cleveland BioLabs
    Healthcare - Public
    Heat Biologics
    Healthcare - Public
    Immune Design
    Healthcare - Public
    Compare competitors

    Curis Online and Social Media Presence

    Embed Graph
    Report incorrect company information

    Curis News and Updates

    November 20, 2018

    Curis to Present at the 60th Annual Meeting of the American Society of Hematology

    LEXINGTON, Mass., Nov. 20, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced three upcoming poster presentations at the 60th annual meeting of...
    October 23, 2018

    Curis to Release Third Quarter Financial Results and Hold Conference Call on November 1, 2018

    LEXINGTON, Mass., Oct. 23, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced that the Company will release its third quarter 2018 financial...
    October 05, 2018

    Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    LEXINGTON, Mass., Oct. 5, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced that on October 1, 2018, the independent Compensation Committee of...
    September 26, 2018

    Curis to Present at the Cantor Fitzgerald Global Healthcare Conference

    LEXINGTON, Mass., Sept. 26, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that the Company will present at the Cantor...
    September 26, 2018

    Optima Curis Awarded Social Impact Investment Certification by Dagda Partners

    September 24, 2018

    Curis Announces Leadership Change

    LEXINGTON, Mass., Sept. 24, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced a change in leadership with the appointment of James E. Dentzer as...
    Show more
    Report incorrect company information

    Curis Blogs

    November 07, 2018

    Curis to Present at 33rd Society for Immunotherapy of Cancer Annual Meeting and Cowen IO NEXT Summit

    November 01, 2018

    Curis Reports Third Quarter 2018 Financial Results

    -- New leadership increasing focus on clinical execution --
    August 28, 2018

    Curis to Present at the Baird 2018 Global Healthcare Conference

    Curis Company Life and Culture

    Report incorrect company information
    Download PDF

     Curis Frequently Asked Questions

    • When was Curis founded?

      Curis was founded in 2000.

    • How many employees does Curis have?

      Curis has 55 employees.

    • What is Curis revenue?

      Latest Curis annual revenue is $9.9 m.

    • What is Curis revenue per employee?

      Latest Curis revenue per employee is $180 k.

    • Who are Curis competitors?

      Competitors of Curis include Ourotech, Cleveland BioLabs and Heat Biologics.

    • Where is Curis headquarters?

      Curis headquarters is located at 4 Maguire Rd, Lexington.

    • Where are Curis offices?

      Curis has an office in Lexington.

    • How many offices does Curis have?

      Curis has 1 office.